Lipocine Stock Performance

LPCN -  USA Stock  

USD 1.12  0.05  4.67%

The company secures a Beta (Market Risk) of 1.0369, which conveys a somewhat significant risk relative to the market. Let's try to break down what Lipocine's beta means in this case. Lipocine returns are very sensitive to returns on the market. As the market goes up or down, Lipocine is expected to follow. Even though it is essential to pay attention to Lipocine price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Lipocine exposes twenty-seven different technical indicators, which can help you to evaluate its performance. Lipocine has an expected return of -0.0796%. Please be advised to verify Lipocine value at risk, as well as the relationship between the skewness and day median price to decide if Lipocine performance from the past will be repeated at some point in the near future.

Lipocine Stock Performance 

 
Refresh
Lipocine Performance
0 of 100
Over the last 90 days Lipocine has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Lipocine is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more

Lipocine Price Channel

Quick Ratio6.03
Fifty Two Week Low0.9680
Target High Price10.00
Fifty Two Week High2.4200
Target Low Price2.50

Lipocine Relative Risk vs. Return Landscape

If you would invest  122.00  in Lipocine on September 8, 2021 and sell it today you would lose (10.00)  from holding Lipocine or give up 8.2% of portfolio value over 90 days. Lipocine is currently does not generate positive expected returns and assumes 3.3163% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Lipocine, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Lipocine is expected to under-perform the market. In addition to that, the company is 3.76 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The DOW is currently generating roughly 0.04 per unit of volatility.

Lipocine Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Lipocine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lipocine, and traders can use it to determine the average amount a Lipocine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.024

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsLPCN
Estimated Market Risk
 3.32
  actual daily
 
 28 %
of total potential
 
2828
Expected Return
 -0.08
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.02
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Lipocine is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lipocine by adding it to a well-diversified portfolio.

About Lipocine Performance

To evaluate Lipocine Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lipocine generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lipocine Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lipocine stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Lipocine's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Return on Investment(89.56) (96.63) 
Return on Average Assets(0.89) (0.91) 
Return on Average Equity(1.70) (1.74) 
Return on Invested Capital(4.72) (5.10) 
Return on Sales(66.77) (68.53) 
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The companys pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Things to note about Lipocine

Checking the ongoing alerts about Lipocine for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lipocine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Lipocine Alerts

Equity Alerts and Improvement Suggestions

Lipocine generated a negative expected return over the last 90 days
Lipocine may become a speculative penny stock
Lipocine has high historical volatility and very poor performance
Lipocine is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 54.99 K. Net Loss for the year was (17.77 M) with loss before overhead, payroll, taxes, and interest of (5.05 M).
Lipocine currently holds about 38.66 M in cash with (14.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Lipocine has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Purchase by Mahesh Patel of 25000 shares of Lipocine
Additionally, see Stocks Correlation. Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Lipocine Stock analysis

When running Lipocine price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine Lipocine value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.